Alternate-Day Buprenorphine Administration. Phase VIII - 9
NCT00000227 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL
Last updated 2016-05-06
Summary
The purpose of this study is to evaluate open buprenorphine dosing with dose choice.
Conditions
- Opioid-Related Disorders
Interventions
- DRUG
-
Buprenorphine
Sponsors & Collaborators
-
National Institute on Drug Abuse (NIDA)
collaborator NIH -
University of Vermont
lead OTHER
Principal Investigators
-
Warren Bickel, Ph.D. · University of Vermont
Study Design
- Purpose
- TREATMENT
- Model
- CROSSOVER
Eligibility
- Min Age
- 25 Years
- Max Age
- 48 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 1994-08-31
Countries
- United States
Study Locations
More Related Trials
-
Alternate Day Buprenorphine Administration, Phase XI - 16
NCT00000234 ·Status: COMPLETED ·Phase: PHASE2
-
Alternate Day Buprenorphine Administration, Phase X - 15
NCT00000233 ·Status: COMPLETED ·Phase: PHASE2
-
Alternate-Day Buprenorphine Administration. Phase I - 3
NCT00000221 ·Status: COMPLETED ·Phase: PHASE1
-
Alternate Day Buprenorphine Administration, Phase XII - 17
NCT00000235 ·Status: COMPLETED ·Phase: PHASE2
-
Alternate-Day Buprenorphine. Phase V - 6
NCT00000224 ·Status: COMPLETED ·Phase: PHASE1
-
Buprenorphine Dose Alteration Study - 1
NCT00000219 ·Status: COMPLETED ·Phase: PHASE1
-
Buprenorphine Pharmacology Related to Addiction Treatment - 21
NCT00000239 ·Status: COMPLETED ·Phase: PHASE2
-
Buprenorphine Pharmacology Related to Addiction Treatment - 18
NCT00000236 ·Status: COMPLETED ·Phase: PHASE2
-
Buprenorphine Maintenance for Opiate Dependence - 6
NCT00000357 ·Status: COMPLETED ·Phase: PHASE2
-
Low-dose Buprenorphine Initiation for Opioid Use Disorder
NCT05450718 ·Status: RECRUITING ·Phase: PHASE4
-
Buprenorphine/Naloxone for Treatment of Opiate Dependence - 9
NCT00000344 ·Status: COMPLETED ·Phase: PHASE2
-
Buprenorphine Dosing Interval - 5
NCT00000209 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluating the Pharmacokinetics and Patient Outcomes of Buprenorphine Microdosing
NCT05307458 ·Status: UNKNOWN
-
Buprenorphine Treatment for Opioid Dependence
NCT02187198 ·Status: COMPLETED ·Phase: PHASE3
-
Blockade Efficacy of Buprenorphine/Naloxone For Opioid Dependence
NCT00134888 ·Status: COMPLETED ·Phase: NA
-
Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment 1 - 1
NCT00000326 ·Status: WITHDRAWN ·Phase: PHASE2
-
Effects of Buprenorphine and Naloxone in Opiate Addicts - 4
NCT00000355 ·Status: COMPLETED ·Phase: PHASE1
-
Oral Buprenorphine as a Novel Low-dose Induction Strategy for Opioid Use Disorder
NCT06086275 ·Status: COMPLETED ·Phase: PHASE1
-
Methadone/Buprenorphine Cross-Over Study - 4
NCT00000208 ·Status: COMPLETED ·Phase: PHASE2
-
Buprenorphine Treatment: A Safe Alternative for Opioid Dependent Pain Patients
NCT01841931 ·Status: TERMINATED ·Phase: PHASE4
-
A Study to Test Whether BI 1356225 Improves Impulsive Behavior in People With Opioid Use Disorder Who Are Taking Buprenorphine
NCT06628622 ·Status: SUSPENDED ·Phase: PHASE1
-
Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment I(2) - 2
NCT00000327 ·Status: WITHDRAWN ·Phase: PHASE2
-
Buprenorphine as a Treatment for Individuals Dependent on Analgesic Opioids
NCT00218101 ·Status: COMPLETED ·Phase: PHASE2
-
Study Comparing Liquid and Tablet Buprenorphine Formulations - 5
NCT00000302 ·Status: COMPLETED ·Phase: PHASE3
-
Phase 1 Study to Evaluate RDC-0313 Coadministered With Buprenorphine to Opioid-Experienced Healthy Adults
NCT01046539 ·Status: COMPLETED ·Phase: PHASE1